EP300 and metabolic dysfunction-associated steatotic liver disease: Published studies indicate CDK2/4 activation is linked to development of NAFLD via regulation of the CCAAT/enhancer binding protein (C/EBP) α-histone acetyltransferase and recruitment of E1A binding protein P300 (EP300) [38,39].